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42 Poster Session-Iour protocol was modified. We report a single-institution experi-
ence using HDM as a preparative regimen in 40 consecutive pts
with MM receiving melphalan on day 22 or day 21. Between
July 2003 and May 2008, 40 pts with MM underwent HDC with
ASCT using HDM either on day –2 (n 5 13) or day –1(n 5 27)
in sequential cohorts. The two groups were similar with respect
to age, gender, ISS stage, number of prior chemotherapy regimens,
prior radiation therapy, FEV1 and DLCOc pre transplantation.
The median CD341 dose (106 /kg) was 5.82 (range, 2.78–
13.68) in the group treated with HDM on day 22 and 3.36 (range,
2.06–10.71) in the group treated with HDM on day 21 (p\0.001).
Pts treated with HDM on day -2 recovered granulocytes at a me-
dian of day 11 (range, 10–12) whereas pts treated on day -1 recov-
ered by day 13 (range, 11–17) post-transplant (p\0.001); this
difference remained significant after adjusting for CD341 dose
(p\0.001). Pts achieved platelet counts more than 20,000/mL at
a median of 12 days (range, 10–27) post-transplant in the group re-
ceiving HDM on day 22 and by 13 days (range, 8–19) in the group
treated on day –1 (p 5 0.74). Pts receiving HDM on day -1 had
worse mucositis as measured by the oral mucositis assessment scale
(p 5 0.027). In the group receiving HDM on day 22, 12 pts (92%)
are alive with a median follow up of 7 mths (range, 3.8–18.7). In the
group receiving HDM on day -1, 24 pts (89%) are alive with a me-
dian follow up of 27.8 mths (range, 1.2–55.4). There was no signif-
icant difference observed in the median relapse-free survival (p 5
0.56) or overall survival (p 5 0.48) between the two groups. Mel-
phalan has a short half-life on the order of 60–90 minutes and
hence administration on day 21 seems feasible. However, our
data indicates that the time to granulocyte engraftment is shorter
in pts receiving HDM on day –2, time to platelet engraftment is
similar and severity of mucositis is lower. These data suggest that
administration of HDM on day 22 may improve hematopoietic re-
covery and decrease mucositis.105
A MD3100: SUCCESSFUL MOBILIZATION IN PATIENTS WHO FAIL STAN-
DARDMOBILIZATIONWITH GOOD TRANSPLANT OUTCOME AND NO SIG-
NIFICANT TOXICITY
Kannarkat, G.T., Beveridge, R., Eichna, D., Scherer, D., Sampl, K.,
Salam, A., Sese, G.B., Lucy Nam, M.H., Mintz, K., Soubra, M.,
Orloff, G. INOVA Fairfax Hospital, Fairfax, VA
AMD3100 reversibly inhibits the binding of SDF-1 to CXCR4,
which normally regulates the migration of hematopoeitic stem cells
(HSC) from the bone marrow. Used in conjunction with G-CSF,
rapid mobilization of CD341HSC into the peripheral bloodstream
can be achieved. In addition to the standard mobilization protocol
with G-CSF, AMD3100 is administered through a compassion-
based protocol at 240 mg/kg in the evening before the first day of phe-
resis and every evening preceding subsequent days of pheresis. At our
institution, we report use of the drug when patients have failed to col-
lect 3.0 million CD341 cells after mobilization with G-CSF alone.
The ten patients (male n 5 5, median age 61 years [range 36–72])
on the study had diagnoses of non-Hodgkins lymphoma (n 5 7)
andHodgkin’s disease (n5 3).Median time from last dose of chemo-
therapy was 2 months [range 5 1–4] and 40 days [range 5 26–118]
between phereses. Before AMD31001 administration, the maxi-
mum total CD341 cell count collected per kg per day was 1.80 ver-
sus 5.80 after treatment [range 0.60–5.80]. Nine out of ten patients
successfully mobilized and proceeded to HSC transplant after use
of AMD3100. Patients who successfully mobilized cells after treat-
ment (median 5 2 days [range 5 1–4]) collected in total a median
of 4.80 million CD341 cells/kg [range 5 2.8–5.8]. For transplant,
a median of 3.30 million CD341 cells/kg [range 2.6–5.8] were in-
fused. Patients achieved ANC and platelet engraftment at a median
of 10 days [range 10–15] and 15 days [range 7–22], respectively.
On average, 2.8 units of red blood cells [range 5 0–6] and 6.2 units
of platelets [range 5 1–18] were required. There was no transplant
related mortality but one patient died at 28 days post transplant
from a myocardial infarction and another patient at 128 days post
transplant from cardiac arrest. No other serious adverse events
were reported. Our institution’s experience with AMD3100 demon-
strates success in mobilizing more CD341 cells in patients who fail
standard protocol, with good transplant outcome and without signif-
icant toxicity.106
SPONTANEOUS AUTOLOGOUS ACUTE GRAFT-VERSUS-HOST DISEASE
(GVHD) IN MULTIPLE MYELOMA (MM) AUTOLOGOUS STEM CELL
TRANSPLANT (ASCT) RECIPIENTS: A SURPRISINGLY HIGH INCIDENCE
Lazarus, H.M.1, Subbiah, S.1, Wakeling, A.1, Cooper, B.W.1,
Ataergin, S.A.1, Laughlin, M.J.1, Kindwall-Keller, T.1, Creger, R.J.1,
Barr, P.1, Gerson, S.L.1, Cooke, K.R.2 1University Hospitals Case Medical
Center, Cleveland, OH; 2Rainbow Babies and Childrens Hospital, Cleve-
land, OH
Five MM patients (pts) age 38–67 yr spontaneously developed au-
tologous acute GVHD limited to the GI tract (N 5 3) or GI tract/
liver (N 5 2) but clinically sparing the skin in all. Onset was docu-
mented via GI tract biopsy in all pts 7–27 days after ASCT. Peak se-
rum bilirubins were 5.5 and 4.5 mg/dL. All pts responded promptly
to prednisone (Pred) 1 or 2 mg/kg/d, or budesonide (Bud) oral ‘‘non-
absorbable’’ corticosteroid, or combination therapy.
Patient and clinical characteristics
Age / Initial Prior CD341 Onset Sites/ GVHD
Gender Stage Therapies x 106/kg aGVHDStage GVHD Therapy55yr/M IIIB k Bort/Dex; Cy 16.4 T17 GI 3 Pred 1/ Bud
62yr/F IIIA IgG k Thal/Dex;
Bort/Dex;
Mel/Pred8.1 T127 GI 4 Bud53yr/F IIIB IgG k Thal/Dex 5.2 T112 GI 3/liver 2 Pred 2
38yr/F IIA IgG k Thal/Dex/Bort 5.3 T19 GI 3/liver 2 Pred 2
67yr/F IIIA IgA l Rev/Dex 15.7 T116 GI 3 Pred 1For initial MM treatment all pts previously received Pred or dexa-
methasone (Dex) plus thalidomide (Thal), lenalidomide (Rev), or
bortezomib (Bort) therapy; all were given cyclophosphamide (Cy)
plus G-CSF for peripheral stem cell (PSC) mobilization followed
by ASCT using amifostine 740 mg/m2 (day T-2 and T-1) and mel-
phalan (Mel) 200 mg/m2 (day T-1). During this same 2006–2008
time period, we performed a total of N5 46 autologous PSC trans-
plants in MM patients age 38–71 yr using the same mobilization and
ASCT regimen; median (range) CD34 cell dose infused was 8.8 (3.5–
23.1) x 106/kg. Exposure to immunomodulatory agents may affect
blood T-regulatory cells (T-regs), cells that protect the host from au-
toimmune disease by suppressing self-reactive cells.The leukapheresis
products collected after PSC mobilization from such patients
may contain low concentrations of T-reg cells. Further, Mel-
containing regimens are associated with a higher incidence of
GVHD in the allogeneic setting (A Shimoni et al. Leuk 21:
2109, 2007). Although rare, autologous GVHD is potentially
a serious complication of ASCT. Despite absence of rash, this
condition should be considered in the differential diagnosis of
MM pts with otherwise unexplained GI symptoms or hepatic
dysfunction in the post-ASCT period. We hypothesize that
the combination of exposure to immunomodulatory agents be-
fore PSC collection and use of Mel in ASCT predispose select
pts to spontaneous autologous acute GVHD.107
FEASIBILITY OF CD34-POSITIVE STEM CELL MOBILIZATION BY ADMIN-
ISTRATION OF AMD3100 SIX HOURS PRIOR TO LEUKAPHERESIS
Chari, A.1, Vendivil, M.1, Clark-Garvey, S.1, Schwartz, J.2, Slotky, R.2,
Diuguid, D.1, Savage, D.1 1NYPH - Columbia University Medical Cen-
ter, New York, NY; 2NYPH - Columbia University Medical Center, New
York, NY
AMD3100, an inhibitor of the SDF-1 chemokine interaction
with the CXCR4 receptor, has allowed successful mobilization of
CD34 stem cells in patients with hematologic malignancies for
whom traditional GCSF based mobilization regimens have failed.
As part of a Compassionate Use Protocol (CUP), we have been
able to collect adequate stem cells in seven such patients. Based
on pharmacokinetic and pharmacodynamic data, the recommended
time of the subcutaneous administration of 240 mcg/kg of
AMD3100 is 10–11 hours before the start of apheresis (in addition
to standard GCSF administration timing). After treating three pa-
tients on this schedule, we found this timing to be impractical for
Poster Session-I 43outpatient AMD3100 administration and the usual daytime leuka-
pheresis at our center. Therefore, we received an institutional
waiver from AnorMed/Genzyme for early morning administration
of AMD3100 followed by leukapheresis approximately six hours
later for all subsequent patients. We compare here the outcomes
of the three patients with previous day (qhs) versus four patients re-
ceiving early morning (qam) administration of AMD3100. The me-
dian age, weight, # prior chemotherapy regimens, highest CD34
cells/ml achieved during most recent mobilization attempt for qhs
vs qam administration were: 58 vs 48.5 years, 80 vs. 76 kg, 2 vs
3.5, and 4.13 vs. 7.21 respectively. Of note, all three patients in
the qhs dosing had received prior radiation whereas none of the
four patients in the qam group did. The median CD34 cells/ml
24 hours prior to the first AMD3100 dose in the two groups was
3.6 vs 4.035. For each group, the median CD34 cells/ml taken im-
mediately prior to apheresis (averaged over the two to four days of
stem cell collection) was 9.22 vs. 25.7. After a median of three days
of collection in both groups, the total number of CD34 cells *106/
kg collected was 2.6 for the qhs group versus 5.57 for the qam
group. These results demonstrate (at least for patients without
prior radiation) the feasibility of a completely daytime, outpatient
peripheral blood stem cell harvest by administering AMD3100 six
hours prior to leukapheresis.108
AUTOGRAFTING IN ACUTE MYELOGENOUS LEUKEMIA: A SINGLE
CENTER EXPERIENCE
Liesveld, J.L., Nichols, D., Sanapala, S., Becker, M.W., Phillips, G.L.
University of Rochester, Rochester, NY
The role of autografting for AML continues to be defined, and its
positioning in therapy as compared to allogeneic transplantation and
chemotherapy approaches is still under investigation. Between 1989
and 2008, 87 autologous stem cell transplants have been performed
at the University of Rochester Medical Center for acute myeloge-
nous leukemia. The mean age at transplant was 39 years with a range
of 2 to 67 years. All but 3 patients were Caucasian. Nine patients
were \ 18 years of age and 9 patients were above age 60 at the
time of transplant. 51% of patients were male. 59% of patients
were transplanted after marrow harvest and 41% after peripheral
blood stem cell collection. Almost all were conditioned with busulfan
and cyclophosphmide. At time of analysis (8/08), 67% of patients
were deceased, and 33% were alive. Seven patients died before day
100; 3 of infection, two of disease recurrence, and two of unknown
causes. In the remaining patients, the mean survival was 1512 6
196 days. In those still living, the mean survival is 2451 6 325 days
(median 2693 days). Of these patients, 4 have undergone allogeneic
stem cell transplantation for recurrent AML and remain in remis-
sion, and one patient received FLAG chemotherapy after a post-
transplant relapse and is still disease free 11 years later. In those
with relapsed disease, where date of relapse was known with preci-
sion, the time range for relapse was from 63 days to greater than
10 years. All but 4 relapses occurred prior to two years. In those pa-
tients who died of causes other than AML relapse, 8 had pulmonary
disease, 2 had sepsis, 3 had fungal infections, 1 had liver failure, and 1
had later onset of ovarian cancer. In 13 cases lost to follow up, the
cause of death is unknown. This single center experience demon-
strates that autologous stem cell support after high dose therapy
for treatment of acute myelogenous leukemia does result in long-
term disease remission in about one third of cases. Late relapses do
occur, and most regimen related mortality manifests early after auto-
grafting.109
CLINICAL OUTCOMES WITH AND WITHOUT SARGRAMOSTIM (GM-CSF)
POST AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTA-
TION
Howle, E.L., Wolf, R.C., Burzynski, J.A., Gastineau, D.A., Lacy, M.Q.,
Gertz, M.A., Dispenzieri, A., Kumar, S., Dingli, D., Buadi, F.,
Inwards, D.J., Ansell, S.M., Micallef, I.N.M., Johnston, P.B.,
Porrata, L.F., Elliott, M.A., Hogan, W.J., Litzow, M.R. Mayo Clinic,
Rochester, MNBackground: Colony stimulating factors (CSF) have substantial
benefits when administered following autologous bone marrow
transplant. With contemporary patient populations, conditioning
regimens and supportive care, the value of CSF administration fol-
lowing autologous peripheral blood stem cell transplant
(APBSCT) is less established. While CSF may slightly decrease
time to neutrophil engraftment, the impact on hospitalization
rate, infections and other clinical outcomes is not clear. On 4/1/
08, a consensus-based practice change eliminated the routine use
of CSF following APBSCT at Mayo Clinic Rochester based on
the hypothesis that this would not significantly impact clinical out-
comes.
Methods: Following IRB approval, a retrospective evaluation
was conducted. All adult patients who received an APBSCT be-
tween 8/1/2007 and 8/31/2008 were reviewed. Patients were ex-
cluded if they refused consent for use of medical records for
research, they received a prior transplant, their primary malig-
nancy was amyloidosis or POEMS, or if they received filgrastim
as prophylaxis following APBSCT. Baseline demographic charac-
teristics and clinical endpoints were collected including: time to
engraftment, number of transfusions, incidence of infection, fever
and duration of therapeutic antimicrobials, incidence of engr-
aftment syndrome, and duration of hospitalization and daily
follow-up.
Results:Of 259 patients reviewed, 140 were included in the anal-
ysis (n 5 66 in GM-CSF group, n 5 74 in no CSF group). 119 pa-
tients were excluded: consent refused (n 5 4), prior transplant (n
5 28), amyloidosis (n 5 38), POEMS (n 5 10), filgrastim adminis-
tered (n 5 30). The majority of patients had a primary diagnosis of
either multiple myeloma or non-Hodgkin lymphoma. Demographic
data between groups was similar. Time to neutrophil engraftment
was a median of 12 days in the GM-CSF group versus 14 days in
the no CSF group (p\0.0001). Other major hematopoietic and
infection-related clinical outcomes were not significantly different
between groups.Clinical Outcomes with and without Sargramostim (GM-CSF)
GM-CSF No CSF p-valueNeutrophil engraftment
in days (median;
interquartile range)12 (11–14) 14 (12.75–17) \0.0001Platelet engraftment
in days (median;
interquartile range)13 (12–15) 14 (12.75–15) 0.39Red blood cell transfusions
(median; interquartile
range)3 (2–4) 3 (2–4) 0.82Platelet transfusions
(median; interquartile
range)3 (2–6) 4 (2–6) 0.21Incidence of microbiologically
documented infection (%)21 32 0.14Incidence of fever (%) 77 66 0.15
Incidence of engraftment
syndrome (%)
3 5 0.49Duration of therapeutic
antimicrobials in days
(median; interquartile range)6 (1.75–8) 6 (0–8) 0.84Duration of hospitalization
in days (median; interquartile
range)2.5 (0–10) 4 (0–8) 0.66Duration of daily follow-up in
days (median; interquartile range)18 (16–21) 19 (18–23) 0.0015Conclusion: Preliminary analysis suggests that eliminating CSF
following APBSCT modestly delays neutrophil engraftment but
does not significantly impact other clinical outcomes. Analysis of
lymphocyte recovery and day 100 mortality between groups is on-
going.
